Monash IVF warns higher costs and slower savings will cut FY27 profit
Monash IVF expects underlying FY27 NPAT to land materially below both FY26 and current analyst consensus after weaker Australian IVF volumes, rising costs and delayed productivity benefits. The company has withdrawn from providing quantitative FY27 earnings guidance.
- Underlying FY27 NPAT expected materially below FY26 and consensus
- Australian stimulated-cycle market contracted 3.2% in Q1 FY27
- 12-month rolling market share held broadly at 19.4%
- $8-11 million annualised productivity target delayed
- Higher depreciation, interest and capacity costs weigh on earnings
Add us as a preferred source on Google
FY27 Profit Warning Removes Quantitative Guidance
Monash IVF Group Limited (ASX:MVF) has warned that underlying FY27 NPAT will be materially below both FY26 and current analyst consensus, putting a sharper edge on the fertility provider’s earnings reset. The company said it could not provide quantitative FY27 guidance because of uncertainty around market activity, cost initiatives and the ramp-up of new facilities.
The warning extends the pressure described in Monash IVF’s FY27 recovery plan, which followed a 41% fall in FY26 underlying NPAT and placed a new productivity program at the centre of the next year’s strategy. Management now says the benefits from that program will take longer to reach earnings than previously anticipated.
Australian IVF Volumes Contracted in the First Quarter
The Australian stimulated-cycle market contracted 3.2% in Q1 FY27 compared with Q4 FY26, with month-to-month volatility continuing. Monash IVF’s 12-month rolling market share remained broadly stable at 19.4%, while industry stimulated cycles decreased 0.5% over the comparable period.
Market share improved in every state except South Australia, where the company said new local competition challenged its long-held position. International operations continued to perform strongly, although from a small base. Trading in October and November improved against Q1 as volumes grew and the productivity program began to contribute, but Monash IVF said the outlook for the rest of FY27 remained uncertain.
Cost Inflation and Capacity Ramp-Up Weigh on Earnings Quality
Fixed costs have risen faster than domestic inflation, particularly in occupancy, wages and insurance. Some key suppliers have also increased prices above inflation, while new capacity in Queensland and Western Australia has generated commissioning costs before reaching full utilisation.
Brisbane operations were closed for about a month in July during the move to a new facility, with training, equipment and consumable costs incurred before reopening. The site is expected to reach a steady state by the end of Q2. Ultrasound North is bringing additional capacity online in stages, while the new Clayton facility remains on track to open to patients in December.
Productivity Target Remains Intact but Benefits Are Delayed
Monash IVF continues to target $8-11 million in annualised pre-tax savings through organisational right-sizing, procurement negotiations and tighter discretionary spending. The target has not been withdrawn, but the company now expects the earnings benefits to be realised over a longer period.
The group also expects depreciation and interest expenses to increase from FY26, reflecting recent capacity investment and higher debt levels. Cremorne theatre utilisation more than doubled, with volumes up 22% between Q4 and Q1, suggesting some assets are gaining traction even as the broader earnings recovery takes longer to appear.
The next scheduled checkpoint is the half-year result and accompanying trading update. By then, the important questions will be whether Brisbane reaches steady-state utilisation, whether the Australian market stabilises and whether cost reductions begin to offset the higher fixed-cost and financing burden.
Bottom Line?
The recovery case now depends less on building capacity and more on filling it quickly enough to absorb higher operating, depreciation and interest costs.
Questions in the middle?
- Can Monash IVF convert the October and November improvement into a sustained second-quarter recovery?
- How quickly will the $8-11 million productivity target begin to flow through reported earnings?
- Will new competition in South Australia lead to a lasting market-share loss or a temporary setback?
Sources
1-
FY27 Trading Update (opens in a new tab)Official market announcement. Monash Ivf Group Limited · 20 Nov 2026 · monashivfgroup.com.au